You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》大摩對內地醫藥及醫療相關股投資評級及目標價 兼列出四大推薦股(表)
摩根士丹利發表研究報告,對內地醫藥及醫療股投資評級及目標價修訂表列如下:

股份|投資評級|目標價(港元)

綠葉製藥(02186.HK)|與大市同步→減持|4.1→3.9元

東陽光藥(01558.HK)|增持→與大市同步|11→8.3元

復星醫藥(02196.HK)|增持→與大市同步|41.8→56元

基石藥業-B(02616.HK)|增持|14→21.5元

康寧傑瑞製藥-B(09966.HK)|增持|21.8→30元

海吉亞醫療(06078.HK)|增持|75→90元

阿里健康(00241.HK)|增持|26→21元

平安好醫生(01833.HK)|增持|134→115元

沛嘉醫療-B(09996.HK)|增持|32.6→36元

三生製藥(01530.HK)|增持→與大市同步|9→8.5元

華潤醫療(01515.HK)|增持→與大市同步|6.6→7.55元

先聲藥業(02096.HK)|增持|13→13.2元

中生製藥(01177.HK)|增持|10元

石四藥集團(02005.HK)|增持|6.3→7元

大摩首選四大醫藥股表列如下:

股份|投資評級|目標價(元)

翰森製藥(03692.HK)|增持|45元

恆瑞醫藥(600276.SH)|增持|94.2元人民幣

信達生物(01801.HK)|增持|104元

藥明生物(02269.HK)|增持|164元

大摩予其他醫藥及醫療股投資評級及目標價如下:

股份|投資評級|目標價(港元)

創新藥及生物科技股

康方生物-B(09926.HK)|增持|70元

康希諾生物-B(06185.HK)|增持|420元

石藥集團(01093.HK)|增持|13.5元

和鉑醫藥-B(02142.HK)|增持|14.8元

諾誠健華-B(09969.HK)|增持|39.2元

李氏大藥廠(00950.HK)|增持|6元

歐康維視生物-B(01477.HK)|增持|36元

榮昌生物-B(09995.HK)|增持|115元

歌禮製藥-B(01672.HK) |與大市同步|3元

研發股

藥明康德(02359.HK)|增持|200元

醫療儀器及診斷股

微創醫療(00853.HK)|增持|71.4元

威高股份(01066.HK)|與大市同步|18.4元

醫院股

錦欣生殖(01951.HK)|增持|19元

醫藥分銷股

國藥控股(01099.HK)|增持|34元

華潤醫藥(03320.HK)|與大市同步|5.7元

醫藥股

康哲藥業(00867.HK)|增持|22元

賽生藥業(06600.HK)|增持|20元

麗珠醫藥(01513.HK)|與大市同步|34.6元

聯邦制藥(03933.HK)|與大市同步|7.6元

原料藥股

海普瑞(09989.HK)|增持|15.1元

中藥股

同仁堂國藥(03613.HK)|增持|16.1元

中國中藥(00570.HK)|增持|6.6元

白雲山(00874.HK)|與大市同步|24元

神威藥業(02877.HK)|與大市同步|7.8元

同仁堂科技(01666.HK)|與大市同步|7元

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account